Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP

An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA220JP or MRA221JP

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.

Inclusion criteria

• RA patients who participated in the previous studies
• Patients who completed the last observation in the previous studies
• Patients who were confirmed to have no problems with safety in the previous studies.

Exclusion criteria

• Patients with Class IV Steinbrocker functional disorder at evaluation within 4 weeks before treatment with the investigational product
• Patients who were not enrolled by 3 months after the last observation day of the previous study